PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure

In this prospective HFrEF study of sacubitril/valsartan initiation compared with recent ACE-I/ARB initiation/dose change, the between-group difference in the primary endpoint, mean KCCQ change at 12weeks, was not statistically significant following adjustment, but sacubitril/valsartan initiation was associated with early improvements in QOL and a higher likelihood of ≥20-pt improvement in KCCQ at 12weeks. These data add additional real-world evidence related to patient-reported outcomes following the initiation of sacubitril/valsartan in routine clinical practice.